Overview

Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

Status:
Not yet recruiting

Trial end date:
2024-10-15

Target enrollment:

Participant gender:

Summary

A5406 hypothesizes that dolutegravir (DTG) 50 mg taken twice daily will provide adequate exposures to maintain viral suppression when dosed with rifapentine (RPT) 1200 mg for HIV-associated TB.

Phase:

Phase 2

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators:

Mylan Inc.
ViiV Healthcare

Treatments:

Dolutegravir
Lamivudine